Targeting RNA polymerase i transcription and the nucleolus for cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 8, 2013, Pages 873-878

  Hannan, Ross D ^a,b,c,d   Drygin, Denis ^e   Pearson, Richard B ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e Cylene Pharmaceuticals   (United States)

Author keywords

5 FU; Actinomycin D; CX 5461; MDM2; Nucleolar stress; Nucleolar surveillance; P53; Ribosomal RNA; RNA polymerase I transcription

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CX 5461; DACTINOMYCIN; DOXORUBICIN; ENZYME INHIBITOR; FLUOROURACIL; HOMOHARRINGTONINE; IRINOTECAN; MITOMYCIN; MITOXANTRONE; OXALIPLATIN; PROTEIN P53; QUARFLOXIN; RAPAMYCIN DERIVATIVE; RG 7112; RNA POLYMERASE; RNA POLYMERASE I INHIBITOR; TEMSIROLIMUS EVEROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG;

CANCER THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; NUCLEOLUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW;

ANTINEOPLASTIC AGENTS; CELL NUCLEOLUS; HUMANS; NEOPLASMS; RNA POLYMERASE I; TRANSCRIPTION, GENETIC;

EID: 84880365124     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.818658     Document Type: Review

References (14)

1. Hannan KM, Sanij E, Rothblum LI, et al. Dysregulation of RNA polymerase I transcription during disease. Biochim Biophys Acta 2013;342-60
2. Derenzini M, Montanaro L, Trere D. What the nucleolus says to a tumour pathologist. Histopathology 2009;753-62
3. Andersen JS, Lyon CE, Fox AH, et al. Directed proteomic analysis of the human nucleolus. Curr Biol 2002;1-11
4. Olson MO. Sensing cellular stress: another new function for the nucleolus? Sci STKE 2004;2004(224):pe10
5. Boisvert FM, van Koningsbruggen S, Navascues J, et al. The multifunctional nucleolus. Nat Rev Mol Cell Biol 2007;574-85 (Pubitemid 46985376)
6. Boulon S, Westman BJ, Hutten S, et al. The nucleolus under stress. Mol Cell 2010;216-27
7. Ruggero D. Revisiting the nucleolus: from marker to dynamic integrator of cancer signaling. Sci Signal 2012;5(241):pe38
8. Burger K, Muhl B, Harasim T, et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J Biol Chem 2010;12416-25
9. Drygin D, Rice WG, Grummt I. The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. Annu Rev Pharmacol Toxicol 2010;131-56
10. Bywater MJ, Pearson RB, McArthur GA, et al. Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat Rev Cancer 2013;299-314
11. Drygin D, Lin A, Bliesath J, et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res 2011;1418-30
12. Bywater MJ, Poortinga G, Sanij E, et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 2012;51-65
13. Tovar C, Graves B, Packman K, et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 2013;2587-97
14. Ray-Coquard I, Blay YJ, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012;1133-40